2026-04-08 18:09:57
Latest Post
OLX India Appoints Varun Sanghi as Non-Executive Chairman
Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Titan Company Limited - Quarterly Update - Q4 FY 2025-26
Lupin Announces the Approval of Dapagliflozin Tablets in the United States
Ashiana Housing Ltd - Operations Update for Q4-FY'26 & FY'26
Stock Report
Ranbaxy Laboratories extends Roots in South Africa with finalisation of Be-Tabs Acquisition
Posted On : 2007-05-08 10:09:29( TIMEZONE : IST )
Ranbaxy Laboratories Ltd has announced that in line with the Company's aggressive international expansion strategy, the approval from South Africa’s Competition Commission has solidified the acquisition of Be-Tabs Pharmaceuticals (Pty) Ltd ("Be-Tabs") by the Company.
The deal is valued at R500 million (USD 70 Million) and will make the Company the fifth largest generic pharmaceutical Company in South Africa.
As part of this acquisition, the Company has concluded a Black Empowerment transaction with a Community Investment Holding (CIH) group Company.
Peter Burema, President of Ranbaxy’s global pharmaceutical division, who signed the deal on May 04, said, "the acquisition of Be-Tabs will ensure that Ranbaxy develops deeper roots in SA and with a strong local flavour."
A key element of the Be-Tabs deal is that it gives the Company local manufacturing capability - making the company one of the few generics pharmaceutical companies to invest in and develop local manufacturing functionality.
The Company is also planning a major upgrade of the Be-Tabs manufacturing facility to bring its factories in line with new standards. With the re-vamp of the Be-Tabs facilities, the company expects to lead the way for generics manufacturing in South Africa.
The acquisition of Be-Tabs substantially strengthens the basket of products that the Company brings to the market - especially in the acute and over the counter product streams. The Company expects to use the brand equity that Be-Tabs has acquired to leverage market share among wholesalers, pharmacies, dispensing doctors and consumers.
The Company established a presence in South Africa in 1996 and has been rewarded with excellent growth in the past decade. The acquisition of Be-Tabs is expected to boost earnings by more than double.
Be-Tabs will remain an independent trading entity and will form one of the three Companies within the Ranbaxy SA Group - the other two being Sonke Pharmaceuticals and Ranbaxy (SA.) (Pty) Ltd.
Be-Tabs Pharmaceuticals (Pty) Ltd is the largest manufacturer of Penicillin formulations in South Africa and markets & manufactures a portfolio of ethical and over-the-counter (OTC) solid-oral and liquid formulations in South Africa.
